The Europe probiotics market is expected to grow at a CAGR of 7.14 percent from 2022 to 2028. - Yahoo Finance
| BIOG-B Stock | SEK 110.60 0.80 0.72% |
About 62% of BioGaia AB's investor base is looking to short. The analysis of current outlook of investing in BioGaia AB suggests that many traders are alarmed regarding BioGaia AB's prospects. The current market sentiment, together with BioGaia AB's historical and current headlines, can help investors time the market. In addition, many technical investors use BioGaia AB stock news signals to limit their universe of possible portfolio assets.
BioGaia |
The Europe probiotics market is expected to grow at a CAGR of 7.14 percent from 2022 to 2028. Yahoo Finance
Read at news.google.com
 |
BioGaia AB Fundamental Analysis
We analyze BioGaia AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioGaia AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioGaia AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
BioGaia AB is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
BioGaia AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioGaia AB stock to make a market-neutral strategy. Peer analysis of BioGaia AB could also be used in its relative valuation, which is a method of valuing BioGaia AB by comparing valuation metrics with similar companies.
Peers
BioGaia AB Related Equities
| CEVI | CellaVision | 0.47 | ||||
| PROB | Probi AB | 0.29 | ||||
| EKTA-B | Elekta AB | 1.21 | ||||
| SECT-B | Sectra AB | 2.73 | ||||
| BIOT | Biotage AB | 2.89 |
Complementary Tools for BioGaia Stock analysis
When running BioGaia AB's price analysis, check to measure BioGaia AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioGaia AB is operating at the current time. Most of BioGaia AB's value examination focuses on studying past and present price action to predict the probability of BioGaia AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioGaia AB's price. Additionally, you may evaluate how the addition of BioGaia AB to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |